Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Prognosis and treatment in high-risk MDS

Drorit Merkel • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine

Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the unmet need for novel treatments in high-risk myelodysplastic syndromes (MDS), with reference to the advantages and disadvantages of using azacitidine. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Drorit Merkel

2:21
Targeted therapy for MDS
Drorit Merkel • 5 Mar 2020
2:17
The etiology and epidemiology of myelodysplastic syndromes
Drorit Merkel • 6 Mar 2020
1:44
Utilizing chromosome banding in MDS
Drorit Merkel • 6 Mar 2020

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals